In 2004 the Committee on the Safety of Medicines (CSM) in the UK issued a warning that olanzapine should not be given to older adults with dementia due to an increased risk of cerebrovascular adverse effects. In the United States, olanzapine has a black box warning of an increased risk of death in older adults. It is not approved for use in patients with dementia-related psychosis.